[1] Forlino A, Marini JC.Osteogenesis imperfecta[J]. Lancet,2016,387(10028):1657-1671. [2] 余长缨,王午喜,韩德宣.成骨不全的诊治进展[J]. 中国儿童保健杂志,2014,22(2):156-158. [3] Forlino A, Cabral WA, Barnes AM, et al.New perspectives on osteogenesis imperfecta[J]. Nat Rev Endocrinol,2011,7(9):540-557. [4] 鲁艳芹, 任秀智,王延宙, 等.成骨不全及其分子机制[J]. 生物化学与生物物理进展,2015,42(6):511-518. [5] Glorieux FH.Osteogenesis imperfecta[J]. Best Pract Res Clin Rheumatol,2008,22(1):85-100. [6] Marini JC, Forlino A, Cabral WA, et al.Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen:regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans[J]. Hum Mutat,2007,28(3):209-221. [7] Steiner RD, Adsit J, Basel D.COL1A1/2-related osteogenesis imperfecta[M].//Adam MP, Ardinger HH, Pagon RA, et al. Gene Reviews,Seattle(WA):University of Washington,1993-2018. [8] 郑峰.成骨不全家系分析并文献复习[J]. 中国全科医学,2012, 15(2):536-537. [9] 吕芳, 李梅.成骨不全症治疗新药研究进展[J]. 国际药学研究杂志,2017, 44(2):173-176. [10] Pereira R, Halford K, Sokolov BP,et al.Phenotypic variability and incomplete penetrance of spontaneous fractures in an inbred strain of transgenic mice expressing a mutated collagen gene[J]. J Clin Invest, 1994, 93(4):1765-1769. |